



The Advance of Clinical Pharmacology in Lung Cancer

Guest Editors:

Prof. Dr. Chih-Jen Yang

1. Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
2. School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3. Lung Cancer Team, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Dr. Yen-Yi Zhen

Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Deadline for manuscript submissions:

closed (20 April 2025)

Message from the Guest Editors

Dear Colleagues,

Lung cancer has always been the deadliest cancer worldwide, largely due to its difficult detection, meaning that it is often only discovered in its advanced stages. Since the development of EGFR TKI-targeted therapy, precision medicine in lung cancer has been increasingly implemented. With the integration of next-generation sequencing (NGS) technologies, various driver genes have been validated in clinical trials and real-world data, showing significant improvements in patient response rates, disease progression-free periods, and even survival rates compared to traditional chemotherapy. Beyond targeted therapies, the combined use of anti-angiogenesis drugs and the development of immunotherapy have set milestones in lung cancer treatment. These advances apply not only to systemic treatments in stage four lung cancer but also to earlier-stage lung cancer patients receiving neoadjuvant or adjuvant therapy, bringing hope for long-term survival. In this Special Issue, we aim to further explore and discuss the pharmacological aspects and usage of these drugs, hoping to contribute to the treatment of lung cancer.

Prof. Dr. Chih-Jen Yang

Dr. Yen-Yi Zhen

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)